In This Article:
As European markets experience a modest uplift, with France's CAC 40 Index seeing a gain of 0.63%, investors are keenly watching for opportunities that might be lurking beneath the surface of broad market movements. In this context, identifying undervalued stocks becomes particularly compelling, offering potential for those looking to invest in assets that may not yet reflect their intrinsic value given the current economic environment.
Top 10 Undervalued Stocks Based On Cash Flows In France
Name | Current Price | Fair Value (Est) | Discount (Est) |
NSE (ENXTPA:ALNSE) | €25.70 | €50.92 | 49.5% |
Wavestone (ENXTPA:WAVE) | €57.70 | €93.34 | 38.2% |
Lectra (ENXTPA:LSS) | €28.90 | €44.00 | 34.3% |
Thales (ENXTPA:HO) | €153.35 | €267.38 | 42.6% |
Tikehau Capital (ENXTPA:TKO) | €23.05 | €32.55 | 29.2% |
Guerbet (ENXTPA:GBT) | €39.65 | €79.11 | 49.9% |
ENENSYS Technologies (ENXTPA:ALNN6) | €0.608 | €1.09 | 44% |
Vivendi (ENXTPA:VIV) | €10.99 | €16.36 | 32.8% |
Figeac Aero Société Anonyme (ENXTPA:FGA) | €5.66 | €9.95 | 43.1% |
OVH Groupe (ENXTPA:OVH) | €5.70 | €7.57 | 24.7% |
Here's a peek at a few of the choices from the screener.
Edenred
Overview: Edenred SE operates a global digital platform for services and payments, catering to companies, employees, and merchants, with a market capitalization of approximately €10.27 billion.
Operations: The company generates revenue primarily through its Business Services segment, which amounted to €2.31 billion.
Estimated Discount To Fair Value: 13.7%
Edenred, priced at €41.24, is observed to be 13.7% below its estimated fair value of €47.76, suggesting a potential undervaluation based on discounted cash flows. Despite a high level of debt and dividends not well covered by earnings, Edenred's forecasted earnings growth at 20.3% per year outpaces the French market's 10.9%. However, its profit margins have declined from last year's 19.9% to 11.6%. Analysts predict a substantial price increase of 49.1%, reflecting optimism in its financial trajectory despite some underlying concerns.
Guerbet
Overview: Guerbet SA is a company focused on the development and marketing of contrast media products, delivery systems, medical devices, and related solutions, with a market capitalization of approximately €498.71 million.
Operations: The company generates €795.65 million from the research, development, production, and sale of contrast media for medical imaging.